News

Keith Vrbicky, MD, Enrolls First U.S. Participant in Moderna’s Phase 2 COVID-19 Vaccine Clinical Trial

The first participant in the Moderna Phase 2 COVID-19 vaccine trial was enrolled this morning by Keith Vrbicky, MD, Meridian (now Velocity Clinical Research) Principal Investigator in Norfolk, NE. Congratulations to Moderna for making remarkable progress on its mRNA vaccine against novel coronavirus. 📰 Full release: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participants-each-age-cohort-dosed-phase

Bounphone “Willow” Chanthavong, MPH, CCRC is the 2019 PharmaTimes Clinical Research Coordinator of the Year

Bounphone Chanthavong (Willow), MPH, CCRC, is the 2019 PharmaTimes Clinical Research Coordinator of the Year! Willow is a research coordinator at Meridian’s (now Velocity Clinical Research) neurology site in Savannah, GA, and won the award on May 4, 2019, after a three-stage competition involving an initial online test, a written essay challenge, and an in-person presentation in … Read more

Results From Meridian (Now Velocity Clinical Research) Studies Featured in Prestigious Publications and Academic Presentations

Results from clinical trials performed at Meridian Clinical Research (now Velocity Clinical Research) sites in Norfolk, NE, Omaha, NE, and Savannah, GA, were recently published in two prestigious medical journals. Brandon Essink, MD, CPI, co-authored an article published in Vaccine. Dr. Essink led a study at the company’s Omaha site as part of a successful clinical … Read more

Brandon Essink, MD, CPI, Co-Authors Article Published in the Journal, Vaccine

Brandon Essink, MD, CPI, co-authored an article recently published in the prestigious journal, Vaccine. A successful meningococcal disease vaccine trial led to this publication, which you can read now at: https://www.sciencedirect.com/science/article/pii/S0264410X18309460?via%3Dihub Title: Breadth of Coverage Against a Panel of 110 Invasive Disease Isolates, Immunogenicity and Safety for 2 and 3 Doses of an Investigational MenABCWY … Read more